Case Report
Allogeneic Hematopoietic Stem Cell Transplantation for a BCR-FGFR1 Myeloproliferative Neoplasm Presenting as Acute Lymphoblastic Leukemia
Table 1
Summary of presenting and clinical features of previously reported BCR-FGFR1 patients.
| | Case | Reference | Age | Gender | Diagnosis | Treatment | Response | Outcome |
| | [6] | 65 | F | Atypical CML | HU/IFN | Unknown | Unknown | | [6] | 51 | F | Atypical CML | HU/IFN | Unknown | Unknown | | [7] | 75 | M | Atypical CML | | | | | AML transformation | HU/cytarabine | Partial hematological response | Unknown | | [8] | 74 | F | Atypical CML | HU | Partial hematological response | Unknown | | [9] | 68 | M | Atypical MPN | | | | | LBC | HU | No hematological response | Unknown | | [10] | 58 | F | Atypical CML | | | | | AML transformation | | Unknown | Unknown | | | | | | Atypical CML | HU/IFN | Minimal hematological and cytogenetic response | | | [11] | 56 | F | | Cytarabine/IFN/ATO | No hematological response | | | | | | | AML transformation | Daunorubicin/cytarabine | Bone marrow aplasia | Deceased | | [12] | 50 | F | CML AP→BC | Unknown | Unknown | Deceased | | [13] | 70 | F | B-ALL | Induction/consolidation/
maintenance chemotherapy | Morphological remission yet persistent t(8;22) | | | Atypical MPN | HU/maintenance | Disease progression | Deceased | | [14] | 57 | F | Atypical MPN | AHSCT | Remission for 42 months post AHSCT | Alive | | [15] | 59 | M | T-LBL/MPN | Cytarabine/daunorubicin/
vincristine/prednisone | Persistent t(8;22) | | | | AHSCT | Cytogenetic remission | Alive | | | | | | B-ALL | HyperCVAD | Remission yet leukocytosis and splenomegaly | | | [16] | 43 | M | Atypical CML | HU/Sorafenib | Partial haematological response/relapse | | | | | | | B-ALL | Sorafenib/FLA-Ida (no G-CSF) | Persistent B-ALL/AML transformation | Deceased | | [17] | 8 | M | MDS/MPN | HU/AHSCT | Remission for 54 months post AHSCT | Alive |
|
|
CML: chronic myeloid leukemia; HU: hydroxyurea; IFN: interferon-alpha; AML: acute myeloid leukemia; MPN: myeloproliferative neoplasm; LBC: lymphoid blast crisis; ATO: arsenic trioxide; AP: accelerated phase; BC: blast crisis; ALL: acute lymphoblastic leukemia; T-LBL, T-lymphoblastic lymphoma; MDS: myelodysplastic syndrome; AHSCT: allogeneic hematopoietic stem cell transplantation; hyperCVAD: hyper-fractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone; FLA-Ida: fludarabine, cytarabine, idarubicin.
|
